With $270M, Beam spinoff Orbital Therapeutics builds RNA medicines as it hunts for partners, more delivery tech

Kyle LaHucik

Senior Reporter

Orbital Therapeutics, the RNA medicines upstart formed by base editing biotech Beam Therapeutics, is out with a $270 million Series A to fuel work across vaccines, protein replacement therapies and immunomodulators.

Backed by big names like ARCH, founded by repeat entrepreneur professors and chaired by the ever-popular board member John Maraganore, Orbital has enough cash to fund all three areas in parallel.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

With $270M, Beam spinoff Orbital Therapeutics builds RNA medicines as it hunts for partners, more delivery tech

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Lawmakers consider limiting how long existing WuXi contracts can continue

Inside CVS Caremark’s move that broke Humira’s hold on the market

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

Medical Affairs: The Critical Link Between Science, Physicians and Patients

With $270M, Beam spin­off Or­bital Ther­a­peu­tics builds RNA med­i­cines as it hunts for part­ners, more de­liv­ery tech

Kyle LaHucik

Senior Reporter

Unlock this article instantly by becoming a free subscriber.

Af­ter eight years with Sanofi, Frank Nes­tle de­parts as CSO, glob­al head of re­search

Law­mak­ers con­sid­er lim­it­ing how long ex­ist­ing WuXi con­tracts can con­tin­ue

In­side CVS Care­mark’s move that broke Hu­mi­ra’s hold on the mar­ket

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

'Big­ger, faster, bet­ter': Iso­mor­phic, Deep­Mind un­veil Al­phaFold 3, go­ing be­yond pro­tein pre­dic­tions

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

With $270M, Beam spinoff Orbital Therapeutics builds RNA medicines as it hunts for partners, more delivery tech

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Lawmakers consider limiting how long existing WuXi contracts can continue

Inside CVS Caremark’s move that broke Humira’s hold on the market

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

'Bigger, faster, better': Isomorphic, DeepMind unveil AlphaFold 3, going beyond protein predictions

Medical Affairs: The Critical Link Between Science, Physicians and Patients